newsfilter
← Latest News
GlobeNewswire·

Aravive Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

HOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that the Company has dosed the first patient in the Phase 2 por